Azilect is a new type of dopamine treatment that is both a Parkinson's disease treatment and an antioxidant supplement. Also known as, Agilect, Azilect treats Parkinson's and dementia by helping to actively protect dopamine levels – the vital transmitting agent for the brain’s signals.
Dopamine treatment is a common way to address dopamine decline as we get older, and the associated conditions that affect the level and effectiveness of dopamine in our brains. Azilect works as a Parkinson's disease treatment as it helps prevent the breakdown of dopamine, the neurotransmitter most affected in Parkinson’s sufferers. It achieves this by inhibiting an enzyme called monoamine oxidase B (or MAO-B).
As a Parkinson's disease treatment, blocking the enzyme MAO-B is key to its effectiveness. During this process it is bio-transformed to aminoindan. Aminoindan appears to have neuroprotective qualities and so protects the brain cells on a wider level - which is, of course, important to overall brain health. Azilect is also believed to be anti apoptotic – which means it positively affects our in-built timer for natural brain cell death. Azilect could, therefore, easily be classed as an antioxidant supplement. This is something you won’t find in comparable treatments on the market.
Despite other treatments not being classed as an antioxidant supplement or anti apoptotic, similar drugs like Deprenyl work well as dopamine protectors, but the net result can be an unwanted amphetamine like effect. Azilect is a non-amphetamine compound. So unlike Deprenyl, there’s no amphetamine bi-product effect, and what’s more, it’s also believed to be 10 – 15 times as potent.
Dopamine is essential for our cognitive functions and fulfils important roles in daily activity. Actions and emotions are all affected by the neurotransmitter, dopamine. We use it for vital functions like: movement, motivation, desire, mood, attention span, learning and working memory.
As dopamine decreases with age and declines more steeply after the age of 40, preserving the available quantity of dopamine is essential for ensuring efficient brain activity. Parkinson's is known to be affected by dopamine levels too, and can progress to dementia - heightening the link between Azilect and dementia prevention.
Azilect offers protection against various types of dementias, through its MAO-B inhibiting activity. MAO-B, or Monoamine oxidase B, is an enzyme that breaks down dopamine in our brains. Azilect inhibits this process and by doing so, protects us from cell deterioration that’s so vital to our cognitive function. Azilect also has an anti-oxidant effect and anti apoptotic properties. It also possesses something called propargylamine moiety. This protects mitochondrial viability (the powerhouse behind cellular development), helping prevent the spread of damaged cells and increasing nerve growth.
This is just one of the reasons why Azilect and dementia prevention are now being studied in clinical research, including trials to study its efficacy in treating Alzheimer’s disease.
In clinical trials, Azilect has also been found to be effective as a monotherapy (i.e. taken on its own), or when taken together with Levodopa / Sinemet, for both early and late stage Parkinson’s disease.
In a trial of 404 subjects treated with 1 or 2mg of Azilect daily for a year, the subjects showed less functional decline than those given a placebo. Another 26-week double-blind study concluded that Azilect was effective at 1 or 2mg dosages. Taken daily it’s very effective against early Parkinson symptoms.
Typically, daily dosages for dementia are 1 mg, going up to a maximum of 2mg daily. Anyone wishing to use Azilect as a preventative measure may want to consider 0.25 mg. to 0.5mg - dependent upon need.
Azilect has shown itself to have minimal side effects – in some studies no more so than those taking the placebo! There has been no sign of what’s known as the ‘cheese effect’ either – a reaction with tyrosine-containing foods such as dairy produce.
Azilect is a proven protector of the brain’s vital cells and the key neurotransmitter dopamine. Used daily, it can prevent dementia and alleviate and improve the symptoms and causes of Parkinson's. And, of course, it is a highly effective antioxidant, too!
Disclaimer: Please note that only your own physician can determine your precise needs, but in order to give you some information these answers are based upon the ‘average person’ and clinical / published results.
Are there any indications that Azilect should not be used with SAMe?
Whilst there are no direct contraindications stated between SAMe and Azilect® (please see manufacturers statements below), it should be known that as SAMe is a potent methylator, (that is to say it can assist one chemical to become another), it is feasible that depending upon dosages used, current condition and length of treatment period etc., that some side effects could become present.
Azilect® clearly states that it should not be used with SSRI or MAO inhibitors, and whilst SAMe is neither of these (actually one of the SAMe manufactures below clearly states that SAMe may be used with SSRI or MAO drugs), it is advisable that some caution be undertaken when combining treatments.
We appreciate that this answer is not that clear, but we are sure you understand that there are many additional elements that can come into play.
My father is doing much, much better. He has replaced his 5mg selegiline-twice per day with rasagiline-once per day. There seems to be no adverse reactions to replacing selegiline immediately with rasagiline...at least in my fathers case. The improvement in my father began on about the fourth day on rasagiline. He was moving better, thinking more clearly, speaking much better and in a better mood, all with no adverse reactions thus far. I think this drug will be a huge success. Since my father has severe short-term memory problems he didn't even remember he was on a new drug so I sincerely doubt this is a placebo effect type thing. I spent the whole day with my father today and he was the best I have seen him in at least two years.